NuCana Shares Plunge Despite Positive Clinical Trial Data

NuCana plc witnessed dramatic trading activity on Wednesday, with its shares swinging by more than 15% before ultimately closing nearly 9% lower. This sharp decline occurred despite the release of encouraging clinical results for the company’s flagship drug candidate, NUC-3373, leaving market observers puzzled by the negative investor response.

The data released on October 14 from the NuTide:303 study appeared fundamentally positive. The research demonstrated significant tumor reduction in heavily pre-treated patients suffering from advanced solid tumors. Furthermore, the combination of NUC-3373 with the PD-1 inhibitor Pembrolizumab exhibited not only promising efficacy but also a favorable safety profile. Contrary to expectations, this news triggered a sell-off, driving the share price down from $5.85 to $5.36—a loss of 8.38%.

The market’s... Read more...